1
|
Chen JR, Zhao JT, Xie ZZ. Integrin-mediated cancer progression as a specific target in clinical therapy. Biomed Pharmacother 2022; 155:113745. [DOI: 10.1016/j.biopha.2022.113745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2022] [Revised: 09/17/2022] [Accepted: 09/21/2022] [Indexed: 11/15/2022] Open
|
2
|
Inhibition of Cancer Cell Adhesion, Migration and Proliferation by a Bispecific Antibody that Targets two Distinct Epitopes on αv Integrins. J Mol Biol 2021; 433:167090. [PMID: 34090922 DOI: 10.1016/j.jmb.2021.167090] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2021] [Revised: 05/27/2021] [Accepted: 05/29/2021] [Indexed: 01/13/2023]
Abstract
Members of the αv family of integrins regulate activation of transforming growth factor beta (TGFβ) and are directly involved in pro-tumorigenic phenotypes. Thus, αv integrins may be therapeutic targets for fibrosis and cancer, yet the isolation of selective inhibitors is currently a challenge. We generated synthetic antibodies selective for αv integrins by phage display selections on cell lines that displayed integrin heterodimers. We identified antibodies that targeted two distinct epitopes on cell-surface αv integrins and partially inhibited cell adhesion mediated by interactions between integrins and the latency-associated peptide, part of the pro-form of TGFβ. Using the isolated antibody paratope sequences we engineered a bispecific antibody capable of binding to both epitopes simultaneously; this antibody potently and completely inhibited cell adhesion mediated by integrins αvβ1, αvβ3 and αvβ5. In addition, the bispecific antibody inhibited proliferation and migration of lung carcinoma lines, where the highest and lowest potencies observed correlated with integrin-αv cell surface expression levels. Taken together, our results demonstrate that phage display selections with live cells can yield high quality anti-integrin antibodies, which we used as biparatopic building blocks to construct a bispecific antibody that strongly inhibited integrin function and may be a therapeutic candidate for cancer and fibrosis.
Collapse
|
3
|
Valianou M, Filippidou N, Johnson DL, Vogel P, Zhang EY, Liu X, Lu Y, Yu JJ, Bissler JJ, Astrinidis A. Rapalog resistance is associated with mesenchymal-type changes in Tsc2-null cells. Sci Rep 2019; 9:3015. [PMID: 30816188 PMCID: PMC6395747 DOI: 10.1038/s41598-019-39418-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2018] [Accepted: 01/24/2019] [Indexed: 01/26/2023] Open
Abstract
Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) are caused by inactivating mutations in TSC1 or TSC2, leading to mTORC1 hyperactivation. The mTORC1 inhibitors rapamycin and analogs (rapalogs) are approved for treating of TSC and LAM. Due to their cytostatic and not cytocidal action, discontinuation of treatment leads to tumor regrowth and decline in pulmonary function. Therefore, life-long rapalog treatment is proposed for the control of TSC and LAM lesions, which increases the chances for the development of acquired drug resistance. Understanding the signaling perturbations leading to rapalog resistance is critical for the development of better therapeutic strategies. We developed the first Tsc2-null rapamycin-resistant cell line, ELT3-245, which is highly tumorigenic in mice, and refractory to rapamycin treatment. In vitro ELT3-245 cells exhibit enhanced anchorage-independent cell survival, resistance to anoikis, and loss of epithelial markers. A key alteration in ELT3-245 is increased β-catenin signaling. We propose that a subset of cells in TSC and LAM lesions have additional signaling aberrations, thus possess the potential to become resistant to rapalogs. Alternatively, when challenged with rapalogs TSC-null cells are reprogrammed to express mesenchymal-like markers. These signaling changes could be further exploited to induce clinically-relevant long-term remissions.
Collapse
Affiliation(s)
- Matthildi Valianou
- Division of Pediatric Nephrology, Department of Pediatrics, College of Medicine, University of Tennessee Health Sciences Center, Memphis, TN, 38103, USA.,Tuberous Sclerosis Complex Center of Excellence, Le Bonheur Children's Hospital, Memphis, TN, 38103, USA
| | - Natalia Filippidou
- Division of Pediatric Nephrology, Department of Pediatrics, College of Medicine, University of Tennessee Health Sciences Center, Memphis, TN, 38103, USA.,Tuberous Sclerosis Complex Center of Excellence, Le Bonheur Children's Hospital, Memphis, TN, 38103, USA
| | - Daniel L Johnson
- Office of Research Molecular Bioinformatics Core, University of Tennessee Health Sciences Center, Memphis, TN, 38103, USA
| | - Peter Vogel
- Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, 38105, USA
| | - Erik Y Zhang
- Division of Pulmonary, Critical Care and Sleep Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA
| | - Xiaolei Liu
- Division of Pulmonary, Critical Care and Sleep Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA
| | - Yiyang Lu
- Division of Pulmonary, Critical Care and Sleep Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA
| | - Jane J Yu
- Division of Pulmonary, Critical Care and Sleep Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA
| | - John J Bissler
- Division of Pediatric Nephrology, Department of Pediatrics, College of Medicine, University of Tennessee Health Sciences Center, Memphis, TN, 38103, USA.,Tuberous Sclerosis Complex Center of Excellence, Le Bonheur Children's Hospital, Memphis, TN, 38103, USA.,Department of Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, 38105, USA
| | - Aristotelis Astrinidis
- Division of Pediatric Nephrology, Department of Pediatrics, College of Medicine, University of Tennessee Health Sciences Center, Memphis, TN, 38103, USA. .,Tuberous Sclerosis Complex Center of Excellence, Le Bonheur Children's Hospital, Memphis, TN, 38103, USA. .,Department of Immunotherapeutics and Biotechnology, School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, 79601, USA.
| |
Collapse
|
4
|
Li JH, Sun SS, Li N, Lv P, Xie SY, Wang PY. MiR-205 as a promising biomarker in the diagnosis and prognosis of lung cancer. Oncotarget 2017; 8:91938-91949. [PMID: 29190887 PMCID: PMC5696153 DOI: 10.18632/oncotarget.20262] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2017] [Accepted: 07/13/2017] [Indexed: 01/09/2023] Open
Abstract
MicroRNA-205 (miR-205) was revealed as a novel diagnostic and prognostic biomarker for lung cancer, but the results in the published papers were inconsistent. This meta-analysis aimed to investigate the diagnostic and prognostic roles of miR-205 in patients with lung cancer. Totally, 16 eligible articles were included, among which 10 articles investigated the diagnostic value of miR-205, 5 articles examined its prognostic values, and 1 article studied both diagnostic and prognostic values. For the diagnostic meta-analysis, the pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and the overall area under the curve of miR-205 for patients with lung cancer were 0.88 (95% CI = 0.78 – 0.94), 0.78 (95% CI = 0.66 – 0.86), 4.00 (95% CI = 2.47 – 6.49), 0.16 (95% CI = 0.08 – 0.30), 25.86 (95% CI = 9.29 – 71.95), and 0.90 (95% CI = 0.87 – 0.92), respectively, indicating that miR-205 is a useful biomarker for diagnostic of lung cancer. The subgroup analysis further demonstrated that miR-205 had an excellent overall accuracy for detection with tissue samples compare with blood samples. For the prognostic meta-analysis, the pooled outcome of the disease-free survival and recurrence-free survival analyses revealed that increased miR-205 levels had a protective role in the prognosis of patients with lung cancer (pooled HR = 0.86, 95% CI: 0.78-0.96, z = 2.83, P = 0.005). In conclusion, miR-205 may be a promising biomarker for detection, predicting the recurrence of patients with lung cancer.
Collapse
Affiliation(s)
- Jing-Hua Li
- Department of Epidemiology, Binzhou Medical University, YanTai, ShanDong 264003, P.R. China.,Key Laboratory of Tumor Molecular Biology in Binzhou Medical University, Department of Biochemistry and Molecular Biology, Binzhou Medical University, YanTai, ShanDong 264003, P.R. China
| | - Shan-Shan Sun
- Department of Epidemiology, Binzhou Medical University, YanTai, ShanDong 264003, P.R. China
| | - Ning Li
- Department of Epidemiology, Binzhou Medical University, YanTai, ShanDong 264003, P.R. China
| | - Peng Lv
- Department of Epidemiology, Binzhou Medical University, YanTai, ShanDong 264003, P.R. China
| | - Shu-Yang Xie
- Key Laboratory of Tumor Molecular Biology in Binzhou Medical University, Department of Biochemistry and Molecular Biology, Binzhou Medical University, YanTai, ShanDong 264003, P.R. China
| | - Ping-Yu Wang
- Department of Epidemiology, Binzhou Medical University, YanTai, ShanDong 264003, P.R. China.,Key Laboratory of Tumor Molecular Biology in Binzhou Medical University, Department of Biochemistry and Molecular Biology, Binzhou Medical University, YanTai, ShanDong 264003, P.R. China
| |
Collapse
|
5
|
Wu YJ, Pagel MA, Muldoon LL, Fu R, Neuwelt EA. High αv Integrin Level of Cancer Cells Is Associated with Development of Brain Metastasis in Athymic Rats. Anticancer Res 2017; 37:4029-4040. [PMID: 28739685 DOI: 10.21873/anticanres.11788] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2017] [Revised: 06/01/2017] [Accepted: 06/14/2017] [Indexed: 12/15/2022]
Abstract
BACKGROUND/AIM Brain metastases commonly occur in patients with malignant skin, lung and breast cancers resulting in high morbidity and poor prognosis. Integrins containing an αv subunit are cell adhesion proteins that contribute to cancer cell migration and cancer progression. We hypothesized that high expression of αv integrin cell adhesion protein promoted metastatic phenotypes in cancer cells. MATERIALS AND METHODS Cancer cells from different origins were used and studied regarding their metastatic ability and intetumumab, anti-αv integrin mAb, sensitivity using in vitro cell migration assay and in vivo brain metastases animal models. RESULTS The number of brain metastases and the rate of occurrence were positively correlated with cancer cell αv integrin levels. High αv integrin-expressing cancer cells showed significantly faster cell migration rate in vitro than low αv integrin-expressing cells. Intetumumab significantly inhibited cancer cell migration in vitro regardless of αv integrin expression level. Overexpression of αv integrin in cancer cells with low αv integrin level accelerated cell migration in vitro and increased the occurrence of brain metastases in vivo. CONCLUSION αv integrin promotes brain metastases in cancer cells and may mediate early steps in the metastatic cascade, such as adhesion to brain vasculature. Targeting αv integrin with intetumumab could provide clinical benefit in treating cancer patients who develop metastases.
Collapse
Affiliation(s)
- Yingjen Jeffrey Wu
- Department of Neurology, Oregon Health & Sciences University, Portland, OR, U.S.A
| | | | - Leslie L Muldoon
- Department of Neurology, Oregon Health & Sciences University, Portland, OR, U.S.A.,Department of Cell, Developmental & Cancer Biology, Oregon Health & Sciences University, Portland, OR, U.S.A
| | - Rongwei Fu
- School of Public Health, Oregon Health & Sciences University, Portland, OR, U.S.A.,Department of Emergency Medicine, Oregon Health & Sciences University, Portland, OR, U.S.A
| | - Edward A Neuwelt
- Department of Neurology, Oregon Health & Sciences University, Portland, OR, U.S.A. .,Veterans Administration Medical Center, Portland, OR, U.S.A.,Department of Neurosurgery, Oregon Health & Sciences University, Portland, OR, U.S.A
| |
Collapse
|
6
|
Yang B, Luo L, Luo W, Zhou Y, Yang C, Xiong T, Li X, Meng X, Li L, Zhang X, Wang Z, Wang Z. The genomic dynamics during progression of lung adenocarcinomas. J Hum Genet 2017; 62:783-788. [PMID: 28381877 PMCID: PMC5537414 DOI: 10.1038/jhg.2017.40] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2016] [Revised: 03/10/2017] [Accepted: 03/12/2017] [Indexed: 01/04/2023]
Abstract
Intra-tumor heterogeneity is a big barrier to precision medicine. To explore the underlying clonal diversity in lung adenocarcinomas, we selected nine individuals with whole-genome sequencing data from primary and matched metastatic tumors as a cohort for study. Similar global pattern of arm-level copy number changes and large variations of somatic single-nucleotide variant between the primary and metastasis are observed in the majority of cases. Importantly, we found breakage-fusion-bridge (BFB) cycles acting as an important mechanism for underlying cancer gene amplification, such as amplification of CDK4, CDKN3 and FGFR1 in early stage. We also identified recurrent focal amplification of gene CCNY derived from BFB in two metastatic tumors, but not in primary tumor. Clonal analysis of case 236T demonstrated that mutational processes are varying with tumor progression. Collectively, our data provide new insights into genetic diversity and potential therapeutic target in lung adenocarcinoma.
Collapse
Affiliation(s)
- Bin Yang
- Department of Breast surgery, China-Japan Union Hospital of Jilin University, Changchun, China
| | | | - Wen Luo
- BGI-Shenzhen, Shenzhen, China
| | | | | | | | | | | | - Lin Li
- BGI-Shenzhen, Shenzhen, China
| | | | | | - Zhixin Wang
- Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, China
| |
Collapse
|
7
|
Lunasin sensitivity in non-small cell lung cancer cells is linked to suppression of integrin signaling and changes in histone acetylation. Int J Mol Sci 2014; 15:23705-24. [PMID: 25530619 PMCID: PMC4284788 DOI: 10.3390/ijms151223705] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2014] [Revised: 12/03/2014] [Accepted: 12/08/2014] [Indexed: 01/04/2023] Open
Abstract
Lunasin is a plant derived bioactive peptide with both cancer chemopreventive and therapeutic activity. We recently showed lunasin inhibits non-small cell lung cancer (NSCLC) cell proliferation in a cell-line-specific manner. We now compared the effects of lunasin treatment of lunasin-sensitive (H661) and lunasin-insensitive (H1299) NSCLC cells with respect to lunasin uptake, histone acetylation and integrin signaling. Both cell lines exhibited changes in histone acetylation, with H661 cells showing a unique increase in H4K16 acetylation. Proximity ligation assays demonstrated lunasin interacted with integrins containing αv, α5, β1 and β3 subunits to a larger extent in the H661 compared to H1299 cells. Moreover, lunasin specifically disrupted the interaction of β1 and β3 subunits with the downstream signaling components phosphorylated Focal Adhesion Kinase (pFAK), Kindlin and Intergrin Linked Kinase in H661 cells. Immunoblot analyses demonstrated lunasin treatment of H661 resulted in reduced levels of pFAK, phosphorylated Akt and phosphorylated ERK1/2 whereas no changes were observed in H1299 cells. Silencing of αv expression in H661 cells confirmed signaling through integrins containing αv is essential for proliferation. Moreover, lunasin was unable to further inhibit proliferation in αv-silenced H661 cells. This indicates antagonism of integrin signaling via αv-containing integrins is an important component of lunasin’s mechanism of action.
Collapse
|